{"id":1317,"date":"2009-01-01T12:04:00","date_gmt":"2009-01-01T11:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2009\/nicht-vermehrt-frakturen-unter-finasterid"},"modified":"2009-01-01T12:04:00","modified_gmt":"2009-01-01T11:04:00","slug":"nicht-vermehrt-frakturen-unter-finasterid","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2009\/nicht-vermehrt-frakturen-unter-finasterid","title":{"rendered":"Nicht vermehrt Frakturen unter Finasterid"},"content":{"rendered":"<p>M\u00e4nner mit benigner Prostata-Hyperplasie (BPH) und einem Organvolumen > 40 ml werden heute oft langzeitig mit Finasterid (Proscar\u00ae) behandelt. Finasterid ist ein 5-alpha-Reduktasehemmer, der die Umwandlung von Testosteron (T) zu Dihydrotestosteron (DHT) in der Prostata und anderen Organen hemmt. DHT ist in der Prostata der entscheidende an die Androgenrezeptoren bindende, nat\u00fcrliche Agonist, der das Prostatawachstum [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>M\u00e4nner mit benigner Prostata-Hyperplasie (BPH) und einem Organvolumen > 40 ml werden heute oft langzeitig mit Finasterid (Proscar\u00ae) behandelt. Finasterid ist ein 5-alpha-Reduktasehemmer, der die Umwandlung von Testosteron (T) zu Dihydrotestosteron (DHT) in der Prostata und anderen Organen hemmt. DHT ist in der Prostata der entscheidende an die Androgenrezeptoren bindende, nat\u00fcrliche Agonist, der das Prostatawachstum [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1474,1090],"class_list":["post-1317","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-finasterid","tag-prostatahyperplasie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1317"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1317\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}